Peter A. Fasching
A5017728105- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- BRCA gene mutations in cancer
- Ovarian cancer diagnosis and treatment
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Genetic Associations and Epidemiology
- Estrogen and related hormone effects
- Cancer-related molecular mechanisms research
- Breast Lesions and Carcinomas
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- AI in cancer detection
- Cancer Risks and Factors
- Nutrition, Genetics, and Disease
- Radiomics and Machine Learning in Medical Imaging
- Endometrial and Cervical Cancer Treatments
- Digital Radiography and Breast Imaging
- RNA modifications and cancer
- Global Cancer Incidence and Screening
- Cancer-related Molecular Pathways
Comprehensive Cancer Center Erlangen
2016-2025
Friedrich-Alexander-Universität Erlangen-Nürnberg
2016-2025
Universitätsklinikum Erlangen
2016-2025
National Cancer Institute
2010-2025
Cancer Clinic
2010-2025
NSABP Foundation
2025
National Center for Tumor Diseases
2019-2025
Helios Hospital Berlin-Buch
2008-2025
Cancer Research Center
2010-2024
Universidad Europea de Madrid
2024
Purpose The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain. Methods Tumor at surgery association with long-term outcome 6,377 patients primary receiving neoadjuvant anthracycline-taxane–based chemotherapy seven randomized trials were analyzed. Results Disease-free (DFS) was significantly superior no invasive situ residuals or nodes (n = 955) compared residual ductal carcinoma only 309), but...
Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients early triple-negative breast cancer. Whether the addition of to neoadjuvant chemotherapy would significantly increase percentage cancer who have a pathological complete response (defined as no invasive negative nodes) at definitive surgery is unclear.
Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy a worse prognosis than those no cancer. Trastuzumab emtansine (T-DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent (DM1), maytansine derivative microtubule inhibitor, provides benefit in patients with metastatic that was previously treated HER2-targeted therapy.
Stratification of women according to their risk breast cancer based on polygenic scores (PRSs) could improve screening and prevention strategies. Our aim was develop PRSs, optimized for prediction estrogen receptor (ER)-specific disease, from the largest available genome-wide association dataset empirically validate PRSs in prospective studies. The development comprised 94,075 case subjects 75,017 control European ancestry 69 studies, divided into training validation sets. Samples were...
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy the setting. Patients and Methods randomly assigned at a two-to-one ratio placebo fulvestrant. The primary end point was locally assessed progression-free survival. Secondary points included overall survival, response rate,...
Background Defective cellular transport processes can lead to aberrant accumulation of trace elements, iron, small molecules and hormones in the cell, which turn may promote formation reactive oxygen species, promoting DNA damage expression key regulatory cancer genes. As uncontrolled proliferation are hallmarks cancer, including epithelial ovarian (EOC), we hypothesized that inherited variation genes contributes EOC risk. Methods In total, samples were obtained from 14,525 case subjects...
Endometriosis is a risk factor for epithelial ovarian cancer; however, whether this extends to all invasive histological subtypes or borderline tumours not clear. We undertook an international collaborative study assess the association between endometriosis and of cancer.
Genetic testing for breast cancer susceptibility is widely used, but many genes, evidence of an association with weak, underlying risk estimates are imprecise, and reliable subtype-specific lacking.
Previous studies have suggested that breast cancer risk factors are associated with estrogen receptor (ER) and progesterone (PR) expression status of the tumors.
Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer: rs999737 and rs2588809 the risk of female cancer rs1314913 male cancer. The aim this study was investigate role RAD51B variants in predisposition, particularly context familial Finland. We sequenced coding region 168 Finnish patients from Helsinki for identification possible recurrent founder mutations. In addition, we studied known rs999737, rs2588809, SNPs haplotypes 44,791 cases 43,583 controls 40...
In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than alone in postmenopausal patients hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. Here we report the results protocol-specified second interim overall survival.
Genetic variations, such as single nucleotide polymorphisms (SNPs) in microRNAs (miRNA) or the miRNA binding sites may affect dependent gene expression regulation, which has been implicated various cancers, including breast cancer, and alter individual susceptibility to cancer. We investigated associations between related SNPs cancer risk. First we evaluated 2,196 a case-control study combining nine genome wide association studies (GWAS). Second, further 42 with suggestive evidence for using...
Purpose Recent advances in DNA sequencing have led to the development of breast cancer susceptibility gene panels for germline genetic testing patients. We assessed frequency mutations 17 predisposition genes, including BRCA1 and BRCA2, a large cohort patients with triple-negative (TNBC) unselected family history or ovarian determine utility those TNBC. Patients Methods TNBC (N = 1,824) were recruited through 12 studies, was sequenced identify mutations. Results Deleterious identified 14.6%...
Circulating tumor cells (CTCs) have been shown to predict reduced survival outcomes in metastatic breast cancer.CTCs were analyzed 2026 patients with early cancer before adjuvant chemotherapy and 1492 after using the CellSearch System. After immuno-magnetic enrichment for expressing epithelial-cell adhesion molecule, CTCs defined as nucleated cytokeratin lacking CD45. The followed a median of 35 months (range = 0-54). Kaplan-Meier analyses log-rank test used analyses. All statistical tests...
Data for multiple common susceptibility alleles breast cancer may be combined to identify women at different levels of risk. Such stratification could guide preventive and screening strategies. However, empirical evidence genetic risk is lacking. We investigated the value using 77 cancer-associated single nucleotide polymorphisms (SNPs) stratification, in a study 33 673 cases 381 control European origin. tested all possible pair-wise multiplicative interactions constructed 77-SNP polygenic...
PURPOSE Trastuzumab, a humanized antibody against the human epidermal growth factor receptor type 2 (HER2), has shown high efficacy in breast cancer. We prospectively investigated its given simultaneously with anthracycline-taxane-based neoadjuvant chemotherapy. PATIENTS AND METHODS Patients operable or locally advanced, HER2-positive tumors were treated preoperatively four cycles of epirubicin/cyclophosphamide followed by docetaxel without capecitabine (EC-T[X]) and trastuzumab 6 mg/kg...
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor A, has shown clinical efficacy in patients with human epidermal receptor 2 (HER2)–negative metastatic breast cancer. We evaluated the efficacy, measured according to rate of pathological complete response (absence invasive and intraductal disease axillary lymph nodes), safety adding bevacizumab neoadjuvant chemotherapy early-stage
Purpose To evaluate efficacy and safety of epirubicin cyclophosphamide followed by paclitaxel trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2 (HER2)–overexpressing breast cancer. Patients Methods centrally confirmed HER2-overexpressing cancer (≥ cm or inflammatory) received four 3-week cycles (90/600 mg/m ) (175 (6 mg/kg) before surgery. Trastuzumab was continued after surgery to complete 1 year treatment. Primary end point pathologic response...